Lilly restructures leadership; Zulueta retiring, Yuffa to lead International, new Neuroscience & Immunology units

ELI LILLY & Co

Alfonso Zulueta, President of Lilly International, to retire effective Dec 26, 2021; succeeded by Ilya Yuffa.
Lilly Bio-Medicines splits into two units: Lilly Neuroscience (led by Anne White) and Lilly Immunology (led by Patrik Jonsson).
Jake Van Naarden promoted to CEO of Loxo Oncology at Lilly and President of Lilly Oncology, joins executive committee.
Donanemab (Alzheimer's) BLA submission planned under accelerated approval pathway; tirzepatide (type 2 diabetes) potential launch cited.
Changes effective Sept 5, 2021; CEO David Ricks cites focus on late-stage pipeline and breakthrough medicines.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alfonso Zulueta

Senior Vice President and President, Lilly International

LLY · ELI LILLY & Co

Effective: 2021-12-26
Filed: August 17, 2021, 7:59 PM ET

On August 11, 2021, Alfonso Zulueta, Senior Vice President and President, Lilly International, of Eli Lilly and Company (the “Company”) notified the Board of Directors of the Company of his intent to retire from his position with the Company effective as of December 26, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Alfonso Zulueta departed as Senior Vice President and President, Lilly International at ELI LILLY & Co.

Action: retire
Role: Senior Vice President and President, Lilly International

Exact text from the filing

On August 11, 2021, Alfonso Zulueta, Senior Vice President and President, Lilly International, of Eli Lilly and Company (the “Company”) notified the Board of Directors of the Company of his intent to retire from his position with the Company effective as of December 26, 2021.

View on SEC.gov

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-21-000175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.